{"id":{"repo_id":"greece","oai_identifier":"oai:10442/0686"},"canonical_url":"https://search.dev.ndltd.org/etd/greece/oai:10442/0686","repository":{"repo_id":"greece","name":"Greek National Archive of PhD Theses","base_url":"https://phdtheses.ekt.gr/eadd_oai/request"},"display":{"title":"ΔΙΕΡΕΥΝΗΣΗ ΤΟΥ ΡΟΛΟΥ ΤΟΥ ΕΙΔΙΚΟΥ ΠΡΟΣΤΑΤΙΚΟΥ ΑΝΤΙΓΟΝΟΥ (PSA) ΣΤΗΝ ΠΑΘΟΛΟΓΙΑ ΤΟΥ ΠΡΟΣΤΑΤΗ","abstract":"WE MEASURED SERUM PROSTATE SPECIFIC ANTIGEN (PSA) FROM 135 MEN (55 PROSTATE CANCER, 39 BENIGN PROSTATE HYPERTROPHY, 9 PROSTATITIS, 32 NORMAL). PSA IS A SPECIFIC-CELL TYPE ANTIGEN OF PROSTATE AND IS MORE SENSITIVE MARKER THAN PROSTATE ACID PHOSPHATASE (PAP)-71% TO 27,3%. PSA CAN NOT SOLVE THE PROBLEM OF PRIMARY DIAGNOSIS OF PROSTATE CANCER BUT IS AN EXCELLENT MARKER TO MONITOR THE EFFECTIVENESS OF THE TREATMENT, IT CAN PREDICT THE PROGRESSION OF PROSTATIC CARCINOMA AND REVEAL ANY CHANGE OF ITS STAGE. IT HAS THE UNIQUE USEFULLNESS OF DETECTING METASTATIC CANCER OF OTHERWISE UNKNOWN ORIGIN AND EARLY ITS ELEVATIONS FOLLOWING TOTAL PROSTATECTOMY OWING TO RECURRENT TUMOR WITH METASTASES. PSA MIGHT BE AS THEMARKER OF CHOICE TO MONITOR THERAPY FOR PROSTATIC CARCINOMA.","abstract_html":"WE MEASURED SERUM PROSTATE SPECIFIC ANTIGEN (PSA) FROM 135 MEN (55 PROSTATE CANCER, 39 BENIGN PROSTATE HYPERTROPHY, 9 PROSTATITIS, 32 NORMAL). PSA IS A SPECIFIC-CELL TYPE ANTIGEN OF PROSTATE AND IS MORE SENSITIVE MARKER THAN PROSTATE ACID PHOSPHATASE (PAP)-71% TO 27,3%. PSA CAN NOT SOLVE THE PROBLEM OF PRIMARY DIAGNOSIS OF PROSTATE CANCER BUT IS AN EXCELLENT MARKER TO MONITOR THE EFFECTIVENESS OF THE TREATMENT, IT CAN PREDICT THE PROGRESSION OF PROSTATIC CARCINOMA AND REVEAL ANY CHANGE OF ITS STAGE. IT HAS THE UNIQUE USEFULLNESS OF DETECTING METASTATIC CANCER OF OTHERWISE UNKNOWN ORIGIN AND EARLY ITS ELEVATIONS FOLLOWING TOTAL PROSTATECTOMY OWING TO RECURRENT TUMOR WITH METASTASES. PSA MIGHT BE AS THEMARKER OF CHOICE TO MONITOR THERAPY FOR PROSTATIC CARCINOMA.","abstract_has_math":false,"creators":["Περιμένης, Πέτρος"],"institution":"University of Patras","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":1988,"date_issued":"1988","date_published":"1988","updated_at":"2026-07-24T02:25:24Z","subjects":["Ειδικό προστατικό αντιγόνο","ΚΑΡΚΙΔΙΚΟΣ ΔΕΙΚΤΗΣ","Καρκίνος προστάτη","Prostate cancer","Prostate specific antigen (PSA)","Tumor markers","Ιατρική και Επιστήμες Υγείας","Κλινική Ιατρική","Medical and Health Sciences","Clinical Medicine"],"languages":["gre"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["10.12681/eadd/0686"],"render_values":[{"text":"10.12681/eadd/0686","href":"https://doi.org/10.12681/eadd/0686","code":true}]}]},"links":{"outbound_url":"http://hdl.handle.net/10442/hedi/0686","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Περιμένης, Πέτρος"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["1988"]},{"key":"dc:publisher","label":"Institution","values":["University of Patras","Πανεπιστήμιο Πατρών"]},{"key":"dc:type","label":"Dc Type","values":["PhD Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Ειδικό προστατικό αντιγόνο","ΚΑΡΚΙΔΙΚΟΣ ΔΕΙΚΤΗΣ","Καρκίνος προστάτη","Prostate cancer","Prostate specific antigen (PSA)","Tumor markers","Ιατρική και Επιστήμες Υγείας","Κλινική Ιατρική","Medical and Health Sciences","Clinical Medicine"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["gre"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["10.12681/eadd/0686","http://hdl.handle.net/10442/hedi/0686"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["WE MEASURED SERUM PROSTATE SPECIFIC ANTIGEN (PSA) FROM 135 MEN (55 PROSTATE CANCER, 39 BENIGN PROSTATE HYPERTROPHY, 9 PROSTATITIS, 32 NORMAL). PSA IS A SPECIFIC-CELL TYPE ANTIGEN OF PROSTATE AND IS MORE SENSITIVE MARKER THAN PROSTATE ACID PHOSPHATASE (PAP)-71% TO 27,3%. PSA CAN NOT SOLVE THE PROBLEM OF PRIMARY DIAGNOSIS OF PROSTATE CANCER BUT IS AN EXCELLENT MARKER TO MONITOR THE EFFECTIVENESS OF THE TREATMENT, IT CAN PREDICT THE PROGRESSION OF PROSTATIC CARCINOMA AND REVEAL ANY CHANGE OF ITS STAGE. IT HAS THE UNIQUE USEFULLNESS OF DETECTING METASTATIC CANCER OF OTHERWISE UNKNOWN ORIGIN AND EARLY ITS ELEVATIONS FOLLOWING TOTAL PROSTATECTOMY OWING TO RECURRENT TUMOR WITH METASTASES. PSA MIGHT BE AS THEMARKER OF CHOICE TO MONITOR THERAPY FOR PROSTATIC CARCINOMA.","ΜΕΤΡΗΘΗΚΕ ΤΟ ΕΙΔΙΚΟ ΠΡΟΣΤΑΤΙΚΟ ΑΝΤΙΓΟΝΟ (PSA) ΑΠΟ 135 ΑΝΔΡΕΣ (32 ΜΑΡΤΥΡΕΣ, 9 ΜΕΠΡΟΣΤΑΤΙΤΙΔΑ, 39 ΜΕ ΥΠΕΡΤΡΟΦΙΑ ΠΡΟΣΤΑΤΗ, ΚΑΙ 55 ΜΕ ΚΑΡΚΙΝΟ). ΤΟ PSA ΠΟΥ ΠΑΡΑΓΕΤΑΙ ΜΟΝΟ ΑΠΟ ΤΟ ΠΡΟΣΤΑΤΙΚΟ ΚΥΤΤΑΡΟ ΒΡΕΘΗΚΕ ΠΙΟ ΕΥΑΙΣΘΗΤΟ (71%) ΑΠΟ ΤΗΝ ΟΞΙΝΗ ΠΡΟΣΤΑΤΙΚΗ ΦΩΣΦΑΤΑΣΗ (27,3%) ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΠΡΟΣΤΑΤΗ. Η ΕΙΔΙΚΟΤΗΤΑ ΤΟΥΣ ΚΥΜΑΙΝΕΤΑΙ ΣΤΑ ΙΔΙΑ ΕΠΙΠΕΔΑ (82% ΕΝΑΝΤΙ 89,7%). ΤΟ PSA ΔΕΝ ΛΥΝΕΙ ΤΟ ΠΡΟΒΛΗΜΑ ΤΗΣ ΠΡΩΙΜΗΣ ΔΙΑΓΝΩΣΗΣ ΤΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΡΟΣΤΑΤΗ ΑΛΛΑ ΕΙΝΑΙ ΣΠΟΥΔΑΙΟΣ ΠΑΡΑΓΟΝΤΑΣ ΕΛΕΓΧΟΥ ΤΗΣ ΑΠΟΤΕΛΕΣΜΑΤΙΚΟΤΗΤΑΣ ΤΗΣ ΑΓΩΓΗΣ ΤΗΣ ΠΡΟΓΝΩΣΗΣ, ΤΗΣ ΕΠΕΚΤΑΣΗΣ ΤΗΣ ΝΟΣΟΥ, ΤΟΥ ΕΛΕΓΧΟΥ ΤΩΝ ΜΕΤΑΣΤΑΣΕΩΝ ΚΑΙ ΤΗΣ ΔΙΑΓΝΩΣΗΣ ΜΕΤΑΣΤΑΤΙΚΩΝ ΚΑΡΚΙΝΩΝ ΑΓΝΩΣΤΗΣ ΑΙΤΙΟΛΟΓΙΑΣ ΠΟΥ ΟΦΕΙΛΕΤΑΙ ΣΤΟΝ ΠΡΟΣΤΑΤΗ. ΠΡΟΤΕΙΝΕΤΑΙ Η ΚΑΘΙΕΡΩΣΗ ΤΗΣ ΑΞΙΟΛΟΓΗΣΗΣ ΤΟΥ PSA ΣΤΗΝ ΚΛΙΝΙΚΗ ΠΡΑΞΗ."]},{"key":"dc:title","label":"Title","values":["ΔΙΕΡΕΥΝΗΣΗ ΤΟΥ ΡΟΛΟΥ ΤΟΥ ΕΙΔΙΚΟΥ ΠΡΟΣΤΑΤΙΚΟΥ ΑΝΤΙΓΟΝΟΥ (PSA) ΣΤΗΝ ΠΑΘΟΛΟΓΙΑ ΤΟΥ ΠΡΟΣΤΑΤΗ","EVALUATION OF PROSTATE SPECIFIC ANTIGEN IN PROSTATIC PATHOLOGY"]}]}],"canonical_facts":{"dc:creator":["Περιμένης, Πέτρος"],"dc:date":["1988"],"dc:description":["WE MEASURED SERUM PROSTATE SPECIFIC ANTIGEN (PSA) FROM 135 MEN (55 PROSTATE CANCER, 39 BENIGN PROSTATE HYPERTROPHY, 9 PROSTATITIS, 32 NORMAL). PSA IS A SPECIFIC-CELL TYPE ANTIGEN OF PROSTATE AND IS MORE SENSITIVE MARKER THAN PROSTATE ACID PHOSPHATASE (PAP)-71% TO 27,3%. PSA CAN NOT SOLVE THE PROBLEM OF PRIMARY DIAGNOSIS OF PROSTATE CANCER BUT IS AN EXCELLENT MARKER TO MONITOR THE EFFECTIVENESS OF THE TREATMENT, IT CAN PREDICT THE PROGRESSION OF PROSTATIC CARCINOMA AND REVEAL ANY CHANGE OF ITS STAGE. IT HAS THE UNIQUE USEFULLNESS OF DETECTING METASTATIC CANCER OF OTHERWISE UNKNOWN ORIGIN AND EARLY ITS ELEVATIONS FOLLOWING TOTAL PROSTATECTOMY OWING TO RECURRENT TUMOR WITH METASTASES. PSA MIGHT BE AS THEMARKER OF CHOICE TO MONITOR THERAPY FOR PROSTATIC CARCINOMA.","ΜΕΤΡΗΘΗΚΕ ΤΟ ΕΙΔΙΚΟ ΠΡΟΣΤΑΤΙΚΟ ΑΝΤΙΓΟΝΟ (PSA) ΑΠΟ 135 ΑΝΔΡΕΣ (32 ΜΑΡΤΥΡΕΣ, 9 ΜΕΠΡΟΣΤΑΤΙΤΙΔΑ, 39 ΜΕ ΥΠΕΡΤΡΟΦΙΑ ΠΡΟΣΤΑΤΗ, ΚΑΙ 55 ΜΕ ΚΑΡΚΙΝΟ). ΤΟ PSA ΠΟΥ ΠΑΡΑΓΕΤΑΙ ΜΟΝΟ ΑΠΟ ΤΟ ΠΡΟΣΤΑΤΙΚΟ ΚΥΤΤΑΡΟ ΒΡΕΘΗΚΕ ΠΙΟ ΕΥΑΙΣΘΗΤΟ (71%) ΑΠΟ ΤΗΝ ΟΞΙΝΗ ΠΡΟΣΤΑΤΙΚΗ ΦΩΣΦΑΤΑΣΗ (27,3%) ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΠΡΟΣΤΑΤΗ. Η ΕΙΔΙΚΟΤΗΤΑ ΤΟΥΣ ΚΥΜΑΙΝΕΤΑΙ ΣΤΑ ΙΔΙΑ ΕΠΙΠΕΔΑ (82% ΕΝΑΝΤΙ 89,7%). ΤΟ PSA ΔΕΝ ΛΥΝΕΙ ΤΟ ΠΡΟΒΛΗΜΑ ΤΗΣ ΠΡΩΙΜΗΣ ΔΙΑΓΝΩΣΗΣ ΤΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΡΟΣΤΑΤΗ ΑΛΛΑ ΕΙΝΑΙ ΣΠΟΥΔΑΙΟΣ ΠΑΡΑΓΟΝΤΑΣ ΕΛΕΓΧΟΥ ΤΗΣ ΑΠΟΤΕΛΕΣΜΑΤΙΚΟΤΗΤΑΣ ΤΗΣ ΑΓΩΓΗΣ ΤΗΣ ΠΡΟΓΝΩΣΗΣ, ΤΗΣ ΕΠΕΚΤΑΣΗΣ ΤΗΣ ΝΟΣΟΥ, ΤΟΥ ΕΛΕΓΧΟΥ ΤΩΝ ΜΕΤΑΣΤΑΣΕΩΝ ΚΑΙ ΤΗΣ ΔΙΑΓΝΩΣΗΣ ΜΕΤΑΣΤΑΤΙΚΩΝ ΚΑΡΚΙΝΩΝ ΑΓΝΩΣΤΗΣ ΑΙΤΙΟΛΟΓΙΑΣ ΠΟΥ ΟΦΕΙΛΕΤΑΙ ΣΤΟΝ ΠΡΟΣΤΑΤΗ. ΠΡΟΤΕΙΝΕΤΑΙ Η ΚΑΘΙΕΡΩΣΗ ΤΗΣ ΑΞΙΟΛΟΓΗΣΗΣ ΤΟΥ PSA ΣΤΗΝ ΚΛΙΝΙΚΗ ΠΡΑΞΗ."],"dc:identifier":["10.12681/eadd/0686","http://hdl.handle.net/10442/hedi/0686"],"dc:language":["gre"],"dc:publisher":["University of Patras","Πανεπιστήμιο Πατρών"],"dc:subject":["Ειδικό προστατικό αντιγόνο","ΚΑΡΚΙΔΙΚΟΣ ΔΕΙΚΤΗΣ","Καρκίνος προστάτη","Prostate cancer","Prostate specific antigen (PSA)","Tumor markers","Ιατρική και Επιστήμες Υγείας","Κλινική Ιατρική","Medical and Health Sciences","Clinical Medicine"],"dc:title":["ΔΙΕΡΕΥΝΗΣΗ ΤΟΥ ΡΟΛΟΥ ΤΟΥ ΕΙΔΙΚΟΥ ΠΡΟΣΤΑΤΙΚΟΥ ΑΝΤΙΓΟΝΟΥ (PSA) ΣΤΗΝ ΠΑΘΟΛΟΓΙΑ ΤΟΥ ΠΡΟΣΤΑΤΗ","EVALUATION OF PROSTATE SPECIFIC ANTIGEN IN PROSTATIC PATHOLOGY"],"dc:type":["PhD Thesis"]},"updated_at":"2026-07-24T02:25:24Z"}